Some searches may not work properly. We apologize for the inconvenience.
My bibliography Save this paperIntegrated Insurance Design in the Presence of Multiple Medical Technologies
Author
Abstract
Suggested Citation
Note: EH
Download full text from publisher
Other versions of this item:
- Tomas J. Philipson & Dana Goldman, 2007. "Integrated Insurance Design in the Presence of Multiple Medical Technologies," American Economic Review, American Economic Association, vol. 97(2), pages 427-432, May.
References listed on IDEAS
- Martin Gaynor & Jian Li & William B. Vogt, 2006.
"Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits,"
The Centre for Market and Public Organisation
07/166, The Centre for Market and Public Organisation, University of Bristol, UK.
- Martin Gaynor & Jian Li & William B. Vogt, 2006. "Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits," NBER Working Papers 12758, National Bureau of Economic Research, Inc.
- Pauly, Mark V. & Held, Philip J, 1990. "Benign moral hazard and the cost-effectiveness analysis of insurance coverage," Journal of Health Economics, Elsevier, vol. 9(4), pages 447-461, December.
- Lichtenberg, Frank R, 1996. "Do (More and Better) Drugs Keep People Out of Hospitals?," American Economic Review, American Economic Association, vol. 86(2), pages 384-388, May.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Frank R. Lichtenberg, 2001.
"The Allocation of Publicly Funded Biomedical Research,"
NBER Chapters, in: Medical Care Output and Productivity,
National Bureau of Economic Research, Inc.
- Frank Lichtenberg, 1997. "The Allocation of Publicly-Funded Biomedical Research," CESifo Working Paper Series 140, CESifo.
- Frank R. Lichtenberg, 1998. "The Allocation of Publicly-Funded Biomedical Research," NBER Working Papers 6601, National Bureau of Economic Research, Inc.
- Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
- James W. Hughes & Michael J. Moore & Edward A. Snyder, 2002.
""Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare,"
NBER Working Papers
9229, National Bureau of Economic Research, Inc.
- James W Hughes & Michael J Moore & Edward A Snyder, 2003. "Napsterizing Pharmaceuticals: Access, Innovation and Consumer Welfare," Levine's Working Paper Archive 618897000000000555, David K. Levine.
- Frank R. Lichtenberg, 2002. "The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output," NBER Working Papers 9139, National Bureau of Economic Research, Inc.
- Di Novi, Cinzia & Leporatti, Lucia & Levaggi, Rosella & Montefiori, Marcello, 2022. "Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 1-14.
- Duggan, Mark, 2005. "Do new prescription drugs pay for themselves?: The case of second-generation antipsychotics," Journal of Health Economics, Elsevier, vol. 24(1), pages 1-31, January.
- Marianne Simonsen & Lars Skipper & Niels Skipper, 2016.
"Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design,"
Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 31(2), pages 320-337, March.
- Simonsen, Marianne & Skipper, Lars & Skipper, Niels, 2010. "Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design," Working Papers 10-1, University of Aarhus, Aarhus School of Business, Department of Economics.
- Marianne Simonsen & Lars Skipper & Niels Skipper, 2010. "Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design," Economics Working Papers 2010-03, Department of Economics and Business Economics, Aarhus University.
- Laurie J. Bates & Kankana Mukherjee & Rexford E. Santerre, 2010. "Medical Insurance Coverage and Health Production Efficiency," Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 77(1), pages 211-229, March.
- Abdülkadi̇r Ci̇van & Bülent Köksal, 2010.
"The effect of newer drugs on health spending: do they really increase the costs?,"
Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 581-595, May.
- Civan, Abdülkadir & Koksal, Bulent, 2007. "The Effect of Newer Drugs on Health Spending: Do They Really Increase the Costs?," MPRA Paper 6846, University Library of Munich, Germany.
- Frank Lichtenberg, 2005.
"The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001,"
International Journal of Health Economics and Management, Springer, vol. 5(1), pages 47-73, January.
- Frank R. Lichtenberg, 2003. "The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001," NBER Working Papers 9754, National Bureau of Economic Research, Inc.
- Dirk Czarnitzki & Katrin Hussinger & Cédric Schneider, 2011.
"Commercializing academic research: the quality of faculty patenting,"
Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 20(5), pages 1403-1437, October.
- Schneider, Cédric & Hussinger, Katrin & Czarnitzki, Dirk, 2008. "Commercializing Academic Research: The Quality of Faculty Patenting," ZEW Discussion Papers 08-069, ZEW - Leibniz Centre for European Economic Research.
- Czarnitzki, Dirk & Hussinger, Katrin & Schneider, Cedric, 2008. "Commercializing Academic Research: The Qaulity of Faculty Patenting," Working Papers 05-2008, Copenhagen Business School, Department of Economics.
- Thierry Nianogo & Albert Okunade & Demba Fofana & Weiwei Chen, 2016. "Determinants of US Prescription Drug Utilization using County Level Data," Health Economics, John Wiley & Sons, Ltd., vol. 25(5), pages 606-619, May.
- Frank Lichtenberg, 2000.
"The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey,"
CESifo Working Paper Series
404, CESifo.
- Frank R. Lichtenberg, 2001. "The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey," NBER Working Papers 8147, National Bureau of Economic Research, Inc.
- Alan M. Garber & Jonathan Skinner, 2008. "Is American Health Care Uniquely Inefficient?," Journal of Economic Perspectives, American Economic Association, vol. 22(4), pages 27-50, Fall.
- STANCIOLE Anderson, 2007. "Health Insurance and Life Style Choices: Identifying the Ex Ante Moral Hazard," IRISS Working Paper Series 2007-10, IRISS at CEPS/INSTEAD.
- Basu, Anirban, 2011.
"Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care,"
Journal of Health Economics, Elsevier, vol. 30(3), pages 549-559, May.
- Anirban Basu, 2011. "Economics of Individualization in Comparative Effectiveness Research and a Basis for a Patient-Centered Health Care," NBER Working Papers 16900, National Bureau of Economic Research, Inc.
- Avi Dor & Mark Pauly & Margaret Eichleay & Philip Held, 2007. "End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF)," International Journal of Health Economics and Management, Springer, vol. 7(2), pages 73-111, September.
- Frank Lichtenberg, 2006. "Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes?," Swiss Journal of Economics and Statistics (SJES), Swiss Society of Economics and Statistics (SSES), vol. 142(V), pages 69-75.
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016.
"Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,"
RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- Mark V. Pauly & Fredric E. Blavin, 2007. "Value Based Cost Sharing Meets the Theory of Moral Hazard: Medical Effectiveness in Insurance Benefits Design," NBER Working Papers 13044, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- I10 - Health, Education, and Welfare - - Health - - - General
NEP fields
This paper has been announced in the following NEP Reports:- NEP-IAS-2007-02-10 (Insurance Economics)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:12870. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.